S
Strongbridge Biopharma
Acquired biopharma developing therapies for rare diseases
About Strongbridge Biopharma
Strongbridge Biopharma was a global, commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases with significant unmet needs. The company was founded in 1996 by Per Marin.
In May 2021, Xeris Pharmaceuticals, Inc. announced a definitive agreement to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267 million. The acquisition was completed in October 2021, and the combined businesses began operating under a new entity named Xeris Biopharma Holdings, Inc. Following the acquisition, former Strongbridge shareholders owned approximately 40% of the new entity, with former Xeris shareholders owning the remaining 60%. John H. Johnson, the former CEO of Strongbridge, joined the Board of Directors of Xeris Biopharma Holdings.
Prior to the acquisition, Strongbridge's portfolio included a rare endocrine franchise and a rare neuromuscular franchise. The main product in the neuromuscular franchise was KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for primary periodic paralysis. The endocrine franchise was centered on RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor for treating endogenous Cushing's syndrome, which was under FDA review at the time of the acquisition. The acquisition was intended to create a more diversified biopharmaceutical company with multiple revenue streams and a robust pipeline, combining Xeris' Gvoke® with Strongbridge's KEVEYIS® and the anticipated launch of RECORLEV®.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1996
- Headquarters
- United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Strongbridge Biopharma in its local ecosystem
The Strongbridge Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
HealthCap
NEA
RA Capital Management- CLCRG LP
Armentum Partners
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Strongbridge Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Strongbridge Biopharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

